Guardant Health to Participate in the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Guardant Health (Nasdaq: GH) announced its participation in the 39th Annual J.P. Morgan Virtual Healthcare Conference, scheduled for January 11 at 7:50 a.m. PT / 10:50 a.m. ET. The event will feature a presentation by the company's management, accessible via a live and archived webcast on their website. Guardant Health specializes in precision oncology, offering blood tests and analytics that enhance cancer care. Their platforms, including Guardant360^® and GuardantOMNI^®, focus on advanced cancer treatment and early detection strategies.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference.

Guardant Health’s management is scheduled to present on Monday, January 11 at 7:50 a.m. Pacific Time / 10:50 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.guardanthealth.com.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has launched liquid biopsy-based Guardant360^®, Guardant360 CDx and GuardantOMNI^® tests for advanced stage cancer patients. These tests fuel development of its LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.

Source: Guardant Health, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201230005327/en/

FAQ

When will Guardant Health present at the J.P. Morgan Virtual Healthcare Conference?

Guardant Health will present on January 11 at 7:50 a.m. Pacific Time / 10:50 a.m. Eastern Time.

How can I access Guardant Health's presentation at the conference?

The presentation can be accessed through a live and archived webcast on the Investors section of Guardant Health's website.

What is the focus area of Guardant Health?

Guardant Health specializes in precision oncology, using advanced blood tests and analytics to improve cancer care.

What products does Guardant Health offer for cancer patients?

Guardant Health offers tests like Guardant360^®, Guardant360 CDx, and GuardantOMNI^® for various stages of cancer treatment.

What is the goal of Guardant Health's LUNAR program?

The LUNAR program aims to provide early detection and treatment options for early stage cancer patients and those at higher risk of developing cancer.